HIV‑1 Coreceptor Tropism, Ultradeep Sequencing
Use
Determines HIV‑1 viral coreceptor tropism by identifying whether a patient’s virus is R5‑tropic (CCR5), X4‑tropic (CXCR4), or dual/mixed (R5/X4), guiding eligibility for CCR5 antagonist therapy (e.g., maraviroc). Genotypic tropism testing using ultradeep sequencing provides a faster, less costly alternative to phenotypic methods, with similar clinical performance in predicting maraviroc response in both treatment‑naïve and experienced populations.
Special Instructions
Not provided.
Limitations
Requires sufficient viral load (plasma HIV‑1 RNA ≥1,000 copies/mL) for reliable V3 loop amplification; if viral load is below threshold, a proviral DNA tropism test may be required. Minority X4 variants must be detected at ≥2% to report as X4 detected. Analytical sensitivity varies with viral load (e.g., 18% X4 at 25,000 copies/mL, 6% at 100,000 copies/mL).
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Not provided.